Meanwhile, the BSE Sensex was up 27.47 points, or 0.13%, to 21,860.08.

On BSE, so far 16,000 shares were traded in the counter, compared with an average volume of 22,022 shares in the past one quarter.

The stock hit a high of Rs 1,194 and a low of Rs 1,141.90 so far during the day. The stock hit a 52-week high of Rs 1,285 on 4 March 2014. The stock hit a 52-week low of Rs 595 on 26 March 2013.

The stock had outperformed the market over the past one month till 18 March 2014, rising 42.48% compared with the Sensex's 5.81% rise. The scrip had outperformed the market in past one quarter, gaining 44.68% as against Sensex's 4.66% rise.

The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.

The recent rise in shares of AstraZeneca Pharma India was triggered by the company's board approving the delisting proposal received from AstraZeneca Pharmaceuticals AB, Sweden (AZP AB), the promoter of the company. The company made the announcement on Saturday, 15 March 2014.

On 1 March 2014, Astrazeneca Pharma India said that its board received a letter from AZP AB, promoter of the company, proposing to delist the equity shares of the company from Indian stock exchanges (BSE, NSE and Bangalore Stock Exchange).

However, on 5 March 2014, Astrazeneca Pharma India announced that its board had deferred the proposed delisting of the firm's shares from the domestic stock exchanges. The company's board decided to seek additional information on the delisting proposal from the parent. Pending receipt of such additional information, consideration of the promoter's letter dated 1 March 2014 was deferred, the Indian company had said in a statement.

AZP AB holds 75% in the company (as per shareholding pattern as on 31 December 2013).

Astrazeneca Pharma India reported a net profit of Rs 1.52 crore in Q3 December 2013 as against net loss of Rs 17.70 crore in Q3 December 2012. Net sales rose 13.3% to Rs 118.88 crore in Q3 December 2013 over Q3 December 2012.

AstraZeneca Pharma India is one of the leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare. The company is involved in both manufacturing and marketing of medicines.